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Objective. Tofacitinib is an oral JAK inhibitor for
the treatment of rheumatoid arthritis (RA). Systemic
inflammation is proposed to play a fundamental role in
the altered lipid metabolism associated with RA; how-
ever, the underlying mechanisms are unknown. We
undertook this study to compare cholesterol and lipo-
protein kinetics in patients with active RA with those in
matched healthy volunteers.
Methods. This was a phase I open-label mechanism-
of-action study. Cholesterol and lipoprotein kinetics
were assessed with 13C-cholesterol and 13C-leucine in-
fusions. RA patients were reevaluated after receiving
oral tofacitinib 10 mg twice daily for 6 weeks.
Results. Levels of high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol,
total cholesterol, and apolipoprotein A-I (Apo A-I) as
well as HDL cholesterol particle number were lower in
RA patients (n  36) than in healthy volunteers (n 
33). In contrast, the cholesterol ester fractional cata-
bolic rate was higher in RA patients, but no differences
were observed in cholesterol ester transfer protein,
cholesterol ester production rate, HDL-associated Apo
A-I fractional catabolic rate, or LDL-associated Apo B
fractional catabolic rate. Following tofacitinib treat-
ment in RA patients, the cholesterol ester fractional
catabolic rate decreased and cholesterol levels in-
creased. The decrease in cholesterol ester fractional
catabolic rate correlated significantly with the increase
in HDL cholesterol. Additionally, HDL cholesterol par-
ticle number increased and markers of HDL cholesterol
function improved.
Conclusion. This is the first study to assess
cholesterol and lipoprotein kinetics in patients with
active RA and matched healthy volunteers. The data
suggest that low cholesterol levels in patients with active
RA may be driven by increases in cholesterol ester
catabolism. Tofacitinib treatment reduced cholesterol
ester catabolism, thereby increasing cholesterol levels
toward those in healthy volunteers, and markers of
antiatherogenic HDL function improved.
ClinicalTrials.gov identifier: NCT01262118.
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Patients with rheumatoid arthritis (RA) have
significantly increased cardiovascular (CV) morbidity
and mortality compared with the general population (1).
Paradoxically, active RA is associated with reduced
levels of low-density lipoprotein (LDL) cholesterol and
total cholesterol (2). High-density lipoprotein (HDL)
cholesterol composition in patients with active RA is
also altered and is associated with changes in the level
and function of several HDL-associated proteins, con-
tributing to the formation of more pro-oxidant,
proatherogenic HDL cholesterol particles (3-5). Treat-
ment of active RA can significantly modify lipid metab-
olism in patients with RA, including increases in circu-
lating cholesterol levels (2,6,7). Systemic inflammation
has been proposed to play a fundamental mechanistic
role in this altered lipid metabolism, but no mechanistic
data in humans have elucidated the potential pathways
underlying this critical observation. This issue comprises
a fundamental paradox in understanding lipid metabo-
lism in the context of inflammatory diseases.
Tofacitinib is an oral JAK inhibitor which mod-
ulates intracellular signaling of multiple key cytokine
receptors involved in the inflammatory cascade (8). In
patients with RA, tofacitinib treatment, either as mono-
therapy or in combination with nonbiologic disease-
modifying antirheumatic drugs (DMARDs), resulted in
significant and clinically meaningful reductions in the
signs and symptoms of RA, improvements in physical
function and patient-reported outcomes, and preserva-
tion of structure, with a consistent safety profile across
studies (9–13). During the tofacitinib clinical develop-
ment program, a proportion of tofacitinib-treated pa-
tients exhibited increases in mean HDL cholesterol,
LDL cholesterol, total cholesterol, apolipoprotein A-I
(Apo A-I), and Apo B levels, mostly occurring within the
first 4–6 weeks of treatment (9–13). The mechanism and
significance of these changes are currently unknown.
Cholesterol movement or flux through the re-
verse cholesterol transport pathway is critical for main-
taining cellular cholesterol homeostasis, not only in the
context of atherosclerotic lesion prevention, but also for
the prevention of toxic levels of cholesterol in every cell.
The central pathway of reverse cholesterol transport
begins with the transfer of free cholesterol and phospho-
lipid to a lipid-poor pre–-HDL particle which consists
principally of Apo A-I and phospholipid (Figure 1, step
Figure 1. Diagram of reverse cholesterol transport. Reverse cholesterol transport starts with the transfer of free cholesterol (FC) and phospholipid
to a lipid-poor pre– high-density lipoprotein (pre–-HDL) particle. Esterification of free cholesterol to cholesterol ester (CE) by lecithin:
cholesterol acyltransferase (LCAT) then generates a mature HDL particle. From this mature HDL particle, cholesterol ester may be transferred to
low-density lipoprotein (LDL) via cholesterol ester transfer protein (CETP) and then delivered to the liver via the LDL receptor (LDLr).
Alternatively, selective cholesterol ester uptake via scavenger receptor class B type I (SR-BI) can deliver cholesterol ester directly to the liver from
HDL, regenerating a lipid-poor apolipoprotein (Apo) A-I–containing particle. Once delivered to the liver, cholesterol can leave the body via biliary
secretion.
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1). The free cholesterol component of the pre–-HDL
particle is then esterified to cholesterol ester by lecithin:
cholesterol acyltransferase (LCAT), generating a ma-
ture HDL particle. From this mature HDL particle,
cholesterol ester may be transferred to LDL via choles-
terol ester transfer protein (CETP) (Figure 1, step 2),
where it can be delivered to the liver via LDL receptor
uptake. Alternatively, cholesterol ester can be delivered
directly to the liver from HDL through selective choles-
terol ester uptake via the CD36 and LIMPII analogous-1
receptor (also known as scavenger receptor class B type
I), regenerating a lipid-poor Apo A-I–containing parti-
cle. Once delivered to the liver, cholesterol can leave the
body via biliary secretion (Figure 1, step 3) (14–16).
The current study used stable isotope tracers
to model in vivo cholesterol and lipoprotein kinetics to
evaluate potential mechanisms for the altered lipid
metabolism in patients with active RA compared with
healthy volunteers (16). Additionally, this study exam-
ined the effects of inflammation suppression with tofac-
itinib treatment on lipid metabolism parameters, as well
as exploratory markers of HDL function and particle
size.
SUBJECTS AND METHODS
Participants. Eligible participants were age 18 years
with a body mass index 35 kg/m2. Lipid-regulating agents,
hormonal forms of contraception, isotretinoin, and supple-
ments containing plant sterols/stanols or cholestin were not
permitted. Participants were excluded from the study if they
had triglycerides 4.52 mmoles/liter after an overnight fast or
total cholesterol 3.62 mmoles/liter after an overnight fast.
Patients with RA had to meet the 1987 revised classi-
fication criteria of the American College of Rheumatology
(17). Other key inclusion criteria included active RA defined
by4 tender/painful joints and4 swollen joints and either an
erythrocyte sedimentation rate (Westergren method) 28
mm/hour or a C-reactive protein level 66.67 nmoles/liter; in
addition, there had to be no evidence of active, latent, or
inadequately treated Mycobacterium tuberculosis infection.
Key exclusion criteria included hemoglobin 100.00 gm/liter,
hematocrit 30%, white blood cell count 3.0  109/liter,
absolute neutrophil count 1.2  109/liter, or platelet count
100  109/liter; glomerular filtration rate 40 ml/minute
(Cockcroft-Gault calculation [18]); and aspartate or alanine
aminotransferase 1.5 times the upper limit of normal.
Use of concomitant intravenous or intramuscular
corticosteroids was not permitted. Low-dose oral cortico-
steroids (10 mg/day prednisone or equivalent) were per-
mitted. Patients were not required to be DMARD naive;
however, all biologic and nonbiologic DMARDs except meth-
otrexate (MTX) had to have been discontinued for a pre-
defined washout period. Patients were permitted to continue
stable (6 weeks prior to the start of the study) background
MTX (7.5–25 mg weekly) therapy. If prior MTX was discon-
tinued, it had to have been discontinued for 4 weeks prior to
the start of the study. Healthy volunteers were matched 1:1
with each patient in the RA cohort for race, age (5 years),
sex, and menopausal status (females).
Study design. This phase I open-label mechanism-of-
action study was conducted at 7 centers in the US and 2 centers
in Hungary. The study was conducted in compliance with the
Declaration of Helsinki, the International Conference on
Harmonisation Guidelines for Good Clinical Practice, and
local country regulations. The final protocol, any amendments,
and informed consent documentation were reviewed and ap-
proved by the institutional review boards and the independent
ethics committees of the investigational centers. All partici-
pants provided written informed consent.
Baseline blood samples were obtained from all partic-
ipants. RA patients then received open-label oral tofacitinib at
10 mg twice daily for 6 weeks, after which blood samples were
obtained again.
The primary objective was to evaluate changes in the
HDL cholesterol concentration and the cholesterol ester pro-
duction rate in RA patients following 6 weeks of tofacitinib at
10 mg twice daily. Secondary objectives included the evalua-
tion of lipid profiles and cholesterol and lipoprotein kinetics
both in RA patients before and after tofacitinib treatment and
in healthy volunteers. The safety profile of tofacitinib in RA
patients was also assessed. Exploratory objectives were to
evaluate biomarkers of HDL function and particle size in RA
patients before and after tofacitinib treatment as well as to
evaluate the relationship between tofacitinib treatment and
changes in HDL cholesterol, LDL cholesterol, and triglyceride
levels and in cholesterol ester production rate.
Collection and assessments. Lipoprotein and choles-
terol concentrations and kinetics. Blood samples were collected
after an overnight fast for Apo and lipoprotein cholesterol
concentrations at baseline in both groups and in RA patients
following tofacitinib treatment. In vivo cholesterol kinetics
were assessed using blood samples obtained before and hourly
throughout a 22-hour continuous infusion (200 mg total)
of labeled free cholesterol (3,4-13C2-cholesterol). In vivo
LDL-associated and HDL-associated Apo kinetics were as-
sessed using blood samples obtained before and 16, 18, and 20
hours after a 20-hour primed continuous infusion of U-13C6-
leucine (1.3 mg/kg body weight priming dose followed by 0.022
mg/kg body weight/minute continuous infusion). Food and
calorie-containing beverages were withheld during both infu-
sion periods.
Blood samples of nonradioactive and isotope-labeled
cholesterol and leucine were analyzed by KineMed. Isotopic
enrichments and pool sizes of plasma and red blood cell free
cholesterol and cholesterol ester were measured by mass
spectrometry and enzymatic colorimetric methods (Wako).
A multicompartment model was used to determine the
cholesterol ester fractional catabolic rate, cholesterol ester
production rate, and total cholesterol efflux rate using SAAM
II software (Simulation, Analysis, and Modeling; SAAM Insti-
tute, University of Washington, Seattle). A description of the
cholesterol kinetic model is detailed elsewhere (16).
HDL biomarkers. Blood samples were collected after
an overnight fast for exploratory biomarkers of HDL function
at baseline in both groups and following tofacitinib treatment
in RA patients. Biomarkers were analyzed by Pacific Biomark-
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ers using the Pacific Biomarkers biomarker panel. LCAT mass,
CETP mass, myeloperoxidase, and total serum amyloid A
(SAA) were determined by sandwich enzyme-linked immuno-
sorbent assay (ELISA). LCAT activity was measured using an
enzymatic method with free cholesterol as the substrate. CETP
activity was determined by a fluorometric method. HDL-
associated SAA was determined by isolating the HDL choles-
terol particles by polyethylene glycol 8000 precipitation fol-
lowed by SAA ELISA.
Lipoprotein particle number and size. Blood samples
obtained after an overnight fast were analyzed by LipoScience
using the LipoScience lipid profile panel to evaluate HDL
cholesterol and LDL cholesterol particle size and number.
Isotope enrichments and kinetic models. A multicom-
partment model was used to determine plasma cholesterol
ester fractional catabolic rate (%/hour), plasma cholesterol
ester production rate (moles/kg body weight/hour), and total
cholesterol efflux rate (moles/kg body weight/hour) using
SAAM II software (16). Flux 1 is defined as the loss of free
cholesterol from the rapidly exchanging free cholesterol pool
in plasma and liver that does not enter into red blood cells or
cholesterol ester. Plasma cholesterol esterification fractional
catabolic rate (k[0,3]) and production rate (flux 3) were
measured from cholesterol ester/free cholesterol enrichment
time profiles and plasma cholesterol ester pool sizes. Total
cholesterol efflux rate was calculated as the sum of flux 1 and
flux 3 and represents the free cholesterol that was mobilized
from extrahepatic tissues into the rapid-turnover free choles-
terol pool in plasma and that did not return to extrahepatic
tissues during the course of the study. Isotope enrichment was
measured in very low-density lipoprotein (VLDL)–associated
Apo B, LDL-associated Apo B, and HDL-associated Apo A-I
fractions. LDL-associated Apo B and HDL-associated Apo
A-I pool sizes were also measured. LDL-associated Apo B and
HDL-associated Apo A-I fractional catabolic rates (%/hour)
were calculated from the enrichment in the Apo B and Apo
A-I fractions and using VLDL-associated Apo B enrichments
as a measure of the hepatic leucine precursor pool. LDL-
associated Apo B and HDL-associated Apo A-I production
rates (mg/kg body weight/minute) were calculated by multiply-
ing the fractional catabolic rates by pool sizes.
Safety. The incidence and severity of all adverse events
(AEs) were recorded. Clinical laboratory tests, evaluation of
vital signs, and physical examinations were performed at
scheduled visits.
Statistical analysis. The full analysis set included all
participants (RA patients and healthy volunteers) for whom
any measurement of cholesterol ester production rate was
available. The safety analysis set consisted of all enrolled
participants.
Analyses of the primary end points, as well as other
pharmacodynamic and kinetic end points, were based on
the full analysis set. The HDL cholesterol concentration
following tofacitinib treatment in RA patients was compared
with baseline levels using a 1-sample t-test. Cholesterol ester
production rate was similarly analyzed. The correlation be-
tween the change in HDL cholesterol level and the change in
cholesterol ester production rate in RA patients was explored
using a scatterplot. P values were calculated using Fisher’s
z-transformation test of correlation coefficient. Paired t-tests
were used to analyze changes in the lipid profile, cholesterol
and lipoprotein kinetics, and exploratory biomarker secondary
end points versus baseline following tofacitinib treatment and
between matched RA patients and healthy volunteers. No
adjustment for multiple comparisons was made.
Given that this was an exploratory study, the sample
size of 30 RA patients and 30 healthy volunteers was not
determined by formal statistical consideration. The power
calculation during protocol development was based on the
assumption of a between-subject coefficient of variation of
18.1% (calculated from a small data set in a different subject
population). As initially designed, a sample size of 30 RA
patients and 15 healthy volunteers would have a power of 92%
to detect a 20% difference at baseline. Owing to larger-than-
anticipated variations in the first 15 RA patients and 15 healthy
volunteers, the number of healthy volunteers was increased to
30; this increased the power from 61% to 79% for the unpaired
analysis and from 55% to 86% for the paired analysis. This trial
(A3921130) is registered with ClinicalTrials.gov identifier
NCT01262118.
RESULTS
Disposition and baseline characteristics of the
subjects. The study started on May 9, 2011 and was
completed on February 1, 2012. A total of 36 RA
patients and 33 healthy volunteers were enrolled, and all
completed the study. Patient demographics and baseline
characteristics are shown in Table 1. Two healthy volun-
Table 1. Demographic and baseline clinical characteristics of the
participants*
RA
patients
(n  36)
Healthy
volunteers
(n  33)
Sex
Male 6 5
Female 30 28
Premenopausal 10 8
Postmenopausal 20 20
Age, years
18–44 9 7
45–64 25 25
65 2 1
Mean  SD 51.4 9.2 51.3  8.9
Race
White 29 27
Black 1 0
Other 6 6
BMI, no. (%)
25.0 kg/m2 13 (36.1) 14 (42.4)
25.0–29.9 kg/m2 14 (38.9) 13 (39.4)
30.0–39.9 kg/m2 9 (25.0) 6 (18.2)
Weight, mean  SD kg 70.4  14.2 68.3  12.0
Tender joint count, mean  SD 25.7  15.8 NA
Swollen joint count, mean  SD 14.8 10.6 NA
* Except where indicated otherwise, values are the number of subjects.
RA  rheumatoid arthritis; BMI  body mass index; NA  not
applicable.
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teers had no cholesterol ester production rate measure-
ments and hence were excluded from the full analysis
set. A total of 24 RA patients (66.7%) and 2 healthy
volunteers (6.1%) received concomitant nonsteroidal
antiinflammatory drugs during the study.
Lipid and lipoprotein concentrations. At base-
line, mean HDL cholesterol, LDL cholesterol, total
cholesterol, and Apo A-I concentrations were lower in
RA patients than in matched healthy volunteers (Table
2). No differences in triglycerides or Apo B concentra-
tions were noted between groups (Table 2). Following
6 weeks of tofacitinib therapy in RA patients, HDL
cholesterol concentrations increased compared with
baseline (P  0.0001). Significant increases in LDL
cholesterol, total cholesterol, Apo B, and Apo A-I
concentrations were also observed (Table 2).
Cholesterol and lipoprotein kinetics. At baseline,
the cholesterol ester fractional catabolic rate was greater
in RA patients than in healthy volunteers (P  0.0085),
whereas no difference in the cholesterol ester produc-
tion rate or cholesterol efflux rate was observed between
cohorts. Increased catabolism of cholesterol ester
(greater cholesterol ester fractional catabolic rate), with-
out a concomitant increase in the production of choles-
terol ester, would be expected to result in lower circu-
lating HDL cholesterol and LDL cholesterol levels, as
noted in Table 2.
Following tofacitinib treatment, the cholesterol
ester fractional catabolic rate decreased (P  0.0014
versus baseline) in RA patients, whereas the cholesterol
ester production rate and cholesterol efflux rate re-
mained unchanged (Table 3). A significant inverse cor-
relation (P  0.0180) was noted between the change in
cholesterol ester catabolism and the change in HDL
cholesterol levels following treatment in a post hoc
analysis (Figure 2A): the larger the decrease in choles-
terol ester catabolism (cholesterol ester fractional cata-
bolic rate), the larger the increase in circulating HDL
cholesterol. Interestingly, an even stronger inverse cor-
relation was observed between the decreases in choles-
terol ester fractional catabolic rate and the increases in
large HDL cholesterol particle numbers (P  0.0019)
(Figure 2B).
At baseline, mean LDL-associated Apo B and
HDL-associated Apo A-I production rates and their
respective fractional catabolic rates were similar be-
Table 3. Descriptive summary of cholesterol and lipoprotein
kinetics*
RA patients
Healthy
volunteers
(n  31)
Baseline
(n  34)
Week 6
(n  33)
Cholesterol ester production
rate, moles/kg/hour
2.83  0.62 2.90 0.62 2.88 0.67
P – 0.6237 0.8879
Cholesterol ester fractional
catabolic rate, %/hour
2.43  0.39 2.23 0.31 2.17 0.36
P – 0.0014 0.0085
Cholesterol efflux rate,
moles/kg/hour
10.39  2.48 10.45 2.79 11.25 3.96
P – 0.5987 0.2542
LDL-associated Apo B
production rate,
mg/kg/hour†
0.49  0.12 0.52 0.12 0.50  0.13
P – 0.3604 0.9097
LDL-associated Apo B
fractional catabolic rate,
%/hour†
1.61  0.37 1.57 0.41 1.50  0.35
P – 0.5680 0.2699
HDL-associated Apo A-I
production rate,
mg/kg/hour†
0.57  0.11 0.65 0.15 0.59 0.16
P – 0.0017 0.4684
HDL-associated Apo A-I
fractional catabolic rate,
%/hour†
1.08  0.22 1.11 0.28 1.02 0.22
P – 0.3031 0.6718
* Values are the mean  SD. All P values are versus RA patients at
baseline. See Table 2 for definitions.
† Data are from 32 RA patients at baseline, 32 RA patients at week 6,
and 30 healthy volunteers.
Table 2. Descriptive summary of lipid and lipoprotein concentrations*
RA patients
Healthy
volunteers
(n  31)
Baseline
(n  36)
Week 6
(n  36)
HDL concentration,
mmoles/liter
1.41  0.32 1.61 0.39 1.64  0.44
P – 0.0001 0.0089
LDL concentration,
mmoles/liter
3.23  0.74 3.70 1.01 3.75  0.94
P – 0.0002 0.0180
Total cholesterol
concentration,
mmoles/liter
5.02  0.84 5.69 1.07 5.74  1.09
P – 0.0001 0.0041
Apo A-I concentration,
gm/liter†
1.17  0.56 1.35 0.58 1.28  0.68
P – 0.0022 0.0014
Apo B concentration,
gm/liter†
0.81  0.42 0.93 0.42 0.82  0.48
P – 0.0138 0.5302
Triglycerides,
mmoles/liter
1.64  0.75 1.71 0.87 1.54  1.09
P – 0.3519 0.6998
* Values are the mean  SD. All P values are versus rheumatoid
arthritis (RA) patients at baseline. HDL  high-density lipoprotein;
LDL  low-density lipoprotein; Apo A-I  apolipoprotein A-I.
† Data are from 35 RA patients at baseline and 32 RA patients at
week 6.
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tween RA patients and healthy volunteers. Following
tofacitinib treatment, only the HDL-associated Apo A-I
production rate had changed (an increase) (P  0.0017)
versus baseline in RA patients (Table 3).
Exploratory analyses. HDL biomarker findings.
Patients with active RA had higher levels of HDL-
associated SAA (P  0.0084), SAA (P  0.0079), and
myeloperoxidase (P  0.0221) and lower LCAT activity
(P  0.0302) and mass (P  0.0013) compared with
healthy volunteers (Table 4). CETP activity and mass
were similar between cohorts.
Following tofacitinib therapy, markers of HDL
cholesterol function improved versus baseline, including
increases in LCAT mass and activity (P  0.0023 and
P  0.0184, respectively) and decreases in total SAA
(P  0.0588) and HDL-associated SAA (P  0.0647).
No differences were noted in myeloperoxidase levels or
CETP activity/mass (Table 4).
Number and size of lipoprotein particles. The total
HDL cholesterol particle number was decreased in RA
patients at baseline compared with healthy volunteers
and increased (P  0.0001) following treatment with
tofacitinib. HDL cholesterol size, LDL cholesterol par-
ticle number, and LDL cholesterol size were not signif-
icantly different in RA patients compared with healthy
volunteers. LDL cholesterol size increased following
tofacitinib treatment (P  0.0379) (Table 4).
Safety findings. Forty-four AEs were reported by
19 RA patients, and 6 AEs were reported by 6 healthy
volunteers. The most common AEs in RA patients were
upper respiratory tract infection (n  7), headache (n 
4), urinary tract infection (n  3), abdominal distension
(n  2), and dyspepsia (n  2); the most common AE in
healthy volunteers was headache (n  4).
There were no serious AEs, permanent discon-
tinuations, or withdrawals due to AEs. Two RA patients
discontinued tofacitinib temporarily due to AEs of mod-
erate severity: one had dizziness, headache, and anxiety,
and the other had a respiratory tract infection. These
AEs resolved before the end of the study.
DISCUSSION
Suppression of circulating cholesterol levels in
the setting of active systemic inflammation has long been
recognized (2,4,19,20). Hudgins et al demonstrated that
endotoxin rapidly and significantly decreased LDL cho-
lesterol and total cholesterol levels in healthy volunteers
concomitant with onset of the inflammatory response
(20). The suppression of cholesterol levels in patients
with active RA has also been increasingly recognized
(2,4,19). When RA therapy is associated with significant
improvement in clinical parameters, it is also often
associated with an increase in circulating cholesterol
levels (2,6,7,19). However, the fundamental mechanisms
driving the increase in circulating cholesterol levels in
effectively treated RA patients remain largely unknown.
We used a recently described novel in vivo assay
to measure cholesterol and lipoprotein kinetics in pa-
tients with active RA and matched healthy volunteers.
We also investigated the effects of tofacitinib, a JAK
inhibitor used in the treatment of RA, on cholesterol
and lipoprotein kinetics. The results reported here sug-
gest for the first time a potential mechanism that may
explain the cholesterol changes in patients with active
RA through changes in cholesterol ester metabolism.
Moreover, the results of the exploratory analyses suggest
Figure 2. Correlation of change in cholesterol ester fractional cata-
bolic rate (FCR) with change in HDL cholesterol levels (A) and
change in large HDL cholesterol particle levels (B) following treat-
ment. See Figure 1 for other definitions.
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potential beneficial effects of tofacitinib treatment in
RA patients on markers of the antiatherogenic function
of HDL.
HDL cholesterol, LDL cholesterol, and total
cholesterol levels in patients with active RA at baseline
were lower than those in healthy volunteers. Following 6
weeks of tofacitinib treatment in RA patients, these
cholesterol levels increased and approached the baseline
measures of the healthy volunteers. RA patients also
had a higher cholesterol ester fractional catabolic rate
compared with healthy volunteers, without any differ-
ences in cholesterol ester production rate. Cholesterol
ester is carried by mature HDL particles and may be
transferred to LDL particles via CETP. Therefore, in-
creased cholesterol ester catabolism, without a concom-
itant increase in cholesterol ester production, would be
expected to result in lower circulating levels of HDL
cholesterol and LDL cholesterol, as was observed in
patients with active RA in the current study. Following 6
weeks of tofacitinib treatment in RA patients, the cho-
lesterol ester fractional catabolic rate decreased and
HDL cholesterol and LDL cholesterol levels increased.
A significant inverse correlation was noted between the
change in cholesterol ester catabolism and the change in
HDL cholesterol levels following treatment: the larger
the decrease in cholesterol ester catabolism, the larger
the increase in circulating HDL cholesterol. Increased
cholesterol ester fractional catabolic rate in the absence
of changes in HDL-associated Apo A-I or LDL-
associated Apo B fractional catabolic rates may reflect
increased selective cholesterol ester uptake by scavenger
receptor class B type I in patients with active RA, which
could have been normalized by tofacitinib.
Accumulating data suggest that the particle func-
tion of HDL may be an important component of the
protective capacity of HDL in preventing CV disease
(21–23). Data in the non-RA population indicate im-
pairment in the antioxidant and efflux functions of HDL
in patients with coronary heart disease (CHD) com-
pared with healthy volunteers (22,23). Khera et al re-
ported that the efflux capacity of HDL was a strong
inverse predictor of both coronary artery disease (CAD)
and carotid intima-media thickness in non-RA patients,
even after adjustment for HDL cholesterol levels and
traditional CV risk factors (23). Li et al found a similar
cross-sectional association of HDL’s efflux capacity with
Table 4. Descriptive summary of exploratory biomarkers and particle size*
RA patients
Healthy
volunteers
(n  31)
Baseline
(n  36)
Week 6
(n  36)
LCAT activity, nmoles/ml/hour 596.03 138.58 642.47 133.57 687.81 120.52
P – 0.0184 0.0302
LCAT mass, g/liter 8,200 2,020 8,980  2,320 9,810 1,540
P – 0.0023 0.0013
CETP activity, pmoles/ml/minute 60.41  8.87 58.87 7.25 58.25  6.58
P – 0.2472 0.3165
CETP mass, g/liter 1,960 520 1,970  450 1,920 570
P – 0.9011 0.6687
SAA concentration, mg/liter 51.93 95.61 24.97 48.96 3.47  2.71
P – 0.0588 0.0079
HDL-associated SAA
concentration, mg/liter
34.76  62.83 17.79  34.45 2.98 2.33
P – 0.0647 0.0084
Myeloperoxidase concentration,
pmoles/liter
1,092.00 1,017.05 942.86 942.64 736.39 344.79
P – 0.4755 0.0221
HDL particles (total), moles/liter 30.66 4.80 33.85  5.51 35.00  5.92
P – 0.0001 0.0020
HDL particle size, nm 9.10  0.40 9.09 0.51 9.20  0.39
P – 0.8573 0.3209
LDL particles (total), nmoles/liter 1,276.19  391.50 1,352.67 498.79 1,357.87 540.11
P – 0.1382 0.3448
LDL particle size, nm 21.01  0.85 21.20 0.97 21.36  0.89
P – 0.0379 0.0639
* Values are the mean SD. All P values are versus RA patients at baseline. LCAT lecithin:cholesterol
acyltransferase; CETP  cholesterol ester transfer protein; SAA  serum amyloid A (see Table 2 for
other definitions).
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prevalent CAD status; however, they also demonstrated
a “paradoxical” association of efflux capacity with future
CV events in a prospective study (24). The latter work
has raised important questions regarding the HDL
“specificity” of a commonly used ex vivo cholesterol
efflux assay (24).
In RA patients, HDL function is abnormal and
has previously been associated with high levels of sys-
temic inflammation—a known link to CV risk in the RA
population (3,25). HDL normally carries a “cargo” of
multiple associated proteins, which may be integral to its
antiatherogenic functions (26). In the setting of active
RA, this protein cargo changes, including the accumu-
lation of several acute-phase proteins and the displace-
ment and/or functional inhibition of normally protective
proteins and enzymes (3,5,26). In the current study,
select protein biomarkers related to HDL function were
examined in exploratory analyses of patients with active
RA (before and after tofacitinib treatment) and healthy
volunteers. HDL-associated SAA levels were higher in
patients with active RA than in healthy volunteers and
decreased following treatment with tofacitinib. These
data are consistent with a prior study by Raterman et al
which showed changes in the HDL protein composition
from proatherogenic to less atherogenic, with specific
decreases in HDL-associated SAA, in RA patients re-
sponding clinically to rituximab therapy (27).
Higher HDL-associated SAA levels have previ-
ously been proposed to contribute to the generation of a
proatherogenic HDL particle, in part through displace-
ment of HDL’s major protein, Apo A-I (21,26,28). Apo
A-I is required for activation of LCAT—an HDL-
associated enzyme that is integral to HDL’s efflux
capacity (21,28). In the current study, LCAT activity and
mass were lower at baseline in patients with active RA
compared with healthy volunteers and increased follow-
ing tofacitinib treatment. While the current work did not
demonstrate differences in the cholesterol efflux rate
between healthy controls and RA patients before and
after therapy, it should be noted that the current meth-
odology may be insensitive to detecting changes in efflux
mediated by reverse cholesterol transport at the cellular
level in cells such as macrophages. In addition, MTX was
allowed in the current study, and it has previously been
shown to abrogate interferon-–induced down-
regulation of ATP-binding cassette transporter protein,
member 1, in THP-1 macrophages (29).
Exploratory biomarker analyses demonstrated
that the total HDL particle number was lower in patients
with active RA than in healthy volunteers and that it
increased following tofacitinib therapy. Smaller LDL
particles were also noted in patients with active RA
compared with healthy volunteers at baseline, and LDL
particle size increased significantly after 6 weeks of
tofacitinib therapy. Lipoprotein particle size and num-
ber have previously been implicated in CV risk across
several studies. The presence of small dense LDL par-
ticles has been strongly associated with increased CHD
risk in the general population, and increased levels of
small dense LDL particles have previously been re-
ported in drug-naive patients with early RA (30). Low
concentrations of small HDL particles have also been
reported in RA patients and have been linked to in-
creased coronary atherosclerosis (31). Although the
current data suggest potentially beneficial CV effects
with tofacitinib treatment on LDL and HDL particle size
and number, these data must be considered preliminary
in nature, with further larger studies warranted.
In summary, this is the first study to assess
cholesterol and lipoprotein kinetics in patients with
active RA and matched healthy volunteers. Our findings
suggest a novel mechanism that may explain the sup-
pression of circulating cholesterol levels in patients with
active RA, in part through increases in cholesterol ester
catabolism. These data may have wider implications
across a range of inflammatory diseases in which lipid
metabolic disturbances are reported and in which vas-
cular comorbidity is described. Tofacitinib treatment in
RA patients was associated with decreases in cholesterol
ester catabolism and increases in cholesterol levels to-
ward the range found in healthy volunteers. Addition-
ally, improvements in markers of antiatherogenic HDL
function were observed, as well as potentially beneficial
effects on lipoprotein particle size and number. Further
investigation of these findings with direct correlation to
CV risk in the RA population is warranted.
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